Toggle Health Problems and D

Hemodialysis associated with very poor mRNA response (wonder if low vitamin D) – March 26, 2021

Hemodialysis Patients Show a Highly Diminished Antibody Response after COVID-19 Compared to Healthy Controls

Preprint doi: https://doi.org/10.1101/2021.03.26.21254259
Benedikt Simon, Harald Rubey, Andreas Treipl, Martin Gromann, Boris Hemedi, Sonja Zehetmayer, Bernhard Kirsch

 Download the PDF from VitaminDWiki

Background and Objectives Hemodialysis patients are prone to infection with SARS-COV2 and show a high probability of a severe course of disease and high mortality when infected. In many countries hemodialysis patients are prioritised in vaccination programs to protect this vulnerable community. However, no hemodialysis patients were included in efficacy trials of SARS CoV-2 vaccines and therefore efficacy and safety data for this patient group are lacking. These data would be critical, since hemodialysis patients showed decreased responses against various other vaccines and this could mean decreased response to SARS CoV-2 vaccines.

Design, setting, participants, and measurements We conducted a prospective cohort study consisting of a group of 81 hemodialysis patients and 80 healthy controls who were vaccinated with mRNA vaccine BNT162b2 (BionTech/Pfizer, 2 doses with an interval of 21 days). Anti-SARS-COV-2 S antibody response in all participants was measured 21 days after the second dose. The groups were compared with univariate quantile regressions and a multiple analysis. Adverse events (AEs) of the vaccination were assessed with a standardized questionnaire. We also performed a correlation of HBs-Antibody response with the SARS-COV-2 antibody response in the hemodialysis patients.

Results Dialysis patients had significantly lower Anti-SARS-COV-2 S antibody titres than healthy control patients 21 days after vaccination with BNT162b2 (median dialysis Patients 171 U/ml versus median controls 2500 U/ml). Age also had a significant but less pronounced influence on antibody titres. Dialysis patients showed less AEs than the control group. No significant correlation was found for Hepatitis B vaccine antibody response and SARS CoV-2 vaccine antibody response.

Conclusions Hemodialysis patients exhibit highly diminished SARS-COV-2 S antibody titres compared to a cohort of controls. Therefore these patients could be much less protected by SARS CoV-2 mRNA vaccination than expected. Alternative vaccination schemes must be considered and preventive measures must be maintained after vaccination.

Created by admin. Last Modification: Wednesday March 31, 2021 15:17:23 GMT-0000 by admin. (Version 5)

Attached files

ID Name Comment Uploaded Size Downloads
15351 Hemodialysis poor response.pdf PDF 2021 admin 31 Mar, 2021 14:30 802.53 Kb 271
See any problem with this page? Report it (WORKS NOV 2021)